PROTHENA CORPORATION PUBLIC LIMITED COMPANY Total Liabilities and Equity
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Total Liabilities and Equity of $302.58 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $302.58M.
- 2026-03-31: Liabilities and Equity $349.89M.
- 2025-12-31: Liabilities and Equity $326.80M.
- 2025-09-30: Liabilities and Equity $352.63M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $302.58M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $349.89M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $326.80M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $352.63M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $399.07M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $495.34M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $547.11M 10-K · filed 2026-02-27 |
| 2024-09-30 | $595.25M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $645.57M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $623.19M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $696.38M 10-K · filed 2025-02-27 |
| 2023-09-30 | $746.92M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $720.65M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $741.59M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $758.03M 10-K · filed 2024-02-22 |
| 2022-09-30 | $554.44M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $549.59M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $581.41M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $609.37M 10-K · filed 2023-02-28 |
| 2021-09-30 | $632.70M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $436.38M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $379.72M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $332.98M 10-K · filed 2022-02-25 |
| 2020-09-30 | $355.78M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $378.93M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $399.42M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $419.27M 10-K · filed 2021-02-26 |
| 2019-09-30 | $450.89M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $462.07M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $459.53M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $498.80M 10-K · filed 2020-03-03 |
| 2018-09-30 | $524.63M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $563.30M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $606.65M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $496.33M 10-K · filed 2019-03-15 |
| 2017-09-30 | $537.68M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $579.00M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $581.95M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $459.98M 10-K · filed 2018-02-26 |
| 2016-09-30 | $479.58M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $502.56M 10-Q · filed 2016-08-02 |
| 2016-03-31 | $491.31M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $385.24M 10-K · filed 2017-02-27 |
| 2015-09-30 | $398.93M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $411.16M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $289.58M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $304.12M 10-K · filed 2016-02-25 |
| 2014-09-30 | $313.60M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $311.69M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $203.81M 10-Q · filed 2014-05-05 |
| 2013-12-31 | $182.41M 10-K · filed 2015-03-13 |
| 2013-09-30 | $107.94M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $117.93M 10-Q · filed 2013-08-13 |
| 2013-03-31 | $124.27M 10-Q · filed 2013-05-15 |
| 2012-12-31 | $129.28M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |